A randomised controlled masked clinical trial of two treatments for osteoarthritis in dogs.
4CYTE™ canine
dog
osteoarthritis
Journal
Australian veterinary journal
ISSN: 1751-0813
Titre abrégé: Aust Vet J
Pays: England
ID NLM: 0370616
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
03
03
2021
received:
12
10
2020
accepted:
09
03
2021
pubmed:
28
4
2021
medline:
6
7
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
The product 4CYTE™ Canine (Interpath Pty Ltd., Ballarat, Victoria, Australia) contains four active ingredients: three marine-derived ingredients and Epiitalis®, which is extracted from the seed of the plant Biota orientalis. Carprofen is a non-steroidal anti-inflammatory drug (NSAID) licensed for the treatment of osteoarthritis in dogs and is the active ingredient in several licensed products. This study aimed to compare the efficacy of 4CYTE Canine with carprofen for the treatment of pain from osteoarthritis. The trial was a randomised, masked, parallel group trial in dogs with naturally occurring osteoarthritis. Sixty-nine dogs with body weight of between 10 and 50 kg were enrolled in the study, of which 66 (95.7%) completed the study. The 4CYTE Canine was administered at 60 mg active/kg daily and carprofen at 2-4 mg/kg daily, with a loading dose of up to 4 mg/kg on the first day. The trial duration was 28 days. The primary outcome was defined as improvement in Owner Lameness Score at Day 28 compared with Day 0. Other outcomes measured included Veterinary Lameness Scores and the Owner Mobility Scores. At Day 28, 14 of 29 (48.3%) dogs that received 4CYTE Canine and 13 of 37 (35.1%) dogs that received carprofen had improved. The 4CYTE Canine was found to be non-inferior to carprofen at Day 14 for the Owner Mobility Score and at Day 28 for all three outcomes. This response pattern suggests that improvement in response to 4CYTE Canine continued between Days 14 and 28. These results support the conclusion that 4CYTE Canine is not inferior to carprofen by end-point clinical efficacy.
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Carbazoles
0
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-272Subventions
Organisme : Interpath Pty Ltd
Informations de copyright
© 2021 Australian Veterinary Association.
Références
Johnston SA, Budsberg SC Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Vet Clin North Am Small Anim Pract 1997;27:841-862.
Pearson W, Orth MW, Karrow NA et al. Anti-inflammatory and chondroprotective effects of nutraceuticals from Sasha's blend in a cartilage explant model of inflammation. Mol Nutr Food Res 2007;51:1020-1030.
Pearson W, Orth MW, Karrow NA et al. Effects of simulated digests of biota orientalis and a dietary nutraceutical on interleukin-1- induced inflammatory responses in cartilage explants. Am J Vet Res 2008;69:1560-1568.
Pearson W, Orth MW, Lindinger MI Evaluation of inflammatory responses induced via intra-articular injection of interleukin-1 in horses receiving a dietary nutraceutical and assessment of the clinical effects of long-term nutraceutical administration. Am J Vet Res 2009;70:848-861.
Pearson W, Lindinger MI Simulated digest of a glucosamine-based equine nutraceutical modifies effect of IL-1 in a cartilage explant model of inflammation. J Vet Pharmacol Ther 2008;31:268-271.
Beths T, Munn R, Bauquier S et al. A pilot study of 4CYTE™ Epiitalis® Forte, a novel nutraceutical, in the management of naturally occurring osteoarthritis in dogs. Aust Vet J 2020;98:591-595. https://doi.org/10.1111/avj.13024.
Anonymous. VICH Topic GL9 (GCP) Guideline on Good Clinical Practices. International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Products, 2001.
Anonymous. Guidelines for the conduct of efficacy studies for non-steroidal anti-inflammatory drugs. Products CfVM, editor. The European Agency for the Evaluation of Medicinal Products, Amsterdam, The Netherlands, 2001.
Anonymous. In: Medicines CV, editor. Freedom of information drug summary NADA 141-053 Rimadyl® - original approval. Food and Drug Administration, Rockville, MD, 1996.
Newcombe RG Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873-890.
Newson R Confidence intervals for rank statistics: percentile slopes, differences, and ratios. Stata J 2006;6:497-520.
Newson R Parameters behind 'nonparametric' statistics: Kemdall's tau, Somers' D and median differences. Stata J 2002;2:45-64.
Ioannidis JP Why most published research findings are false. PLoS Med 2005;2:e124.
Lascelles BD, Roe SC, Smith E et al. Evaluation of a pressure walkway system for measurement of vertical limb forces in clinically normal dogs. Am J Vet Res 2006;67:277-282.
Nelson SA, Krotscheck U, Rawlinson J et al. Long-term functional outcome of Tibial plateau leveling osteotomy versus Extracapsular repair in a heterogeneous population of dogs. Vet Surg 2013;42:38-50.
Vasseur PB, Johnson AL, Budsberg SC et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995;206:807-811.
Reymond N, Speranza C, Gruet P et al. Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. J Vet Pharmacol Ther 2012;35:175-183.